By Yifan Wang
Shanghai Fosun Pharmaceutical (Group) Co. said its net profit rose 42% in the third quarter, thanks to better sales of new products, as well as income contribution from the sales of Covid-19 vaccines.
Net profit for the period was at CNY1.08 billion yuan (US$169.2 million), the drug maker said late Tuesday.
Revenue rose 25% to CNY10.10 billion.
Fosun Pharma has been licensed by BioNTech to exclusively develop and commercialize the German firm's COVID-19 vaccines in China, Hong Kong, Macau and Taiwan.
Write to Yifan Wang at yifan.wang@wsj.com
(END) Dow Jones Newswires
10-26-21 2010ET